NanoViricides
NNVCNanoViricides Inc. is a clinical-stage biotechnology company specializing in the development of host-mimetic nanomachines designed to dismantle targeted viruses without relying on the human immune system.
Table of contents
Earnings
Next report
Sep 2, 2026 (in a month)Competitors
By market cap
Profile
NanoViricides Inc. is a clinical-stage biotechnology company specializing in the development of host-mimetic nanomachines designed to dismantle targeted viruses without relying on the human immune system. The company's proprietary technology platform creates chemical nanostructures that mimic cellular receptors to trap and neutralize viruses before they can infect human cells. Their primary focus is on broad-spectrum antiviral therapies that address a wide range of viral pathogens by targeting common attachment mechanisms.
A clinical-stage innovator utilizing a unique 'nanomachine' approach that differentiates itself from traditional antibody or small-molecule antiviral therapies.
Questions, answered.
- What is NanoViricides's market cap?
- NanoViricides (NNVC) has a market capitalization of $35.4M and trades on AMEX.
- Who are NanoViricides's competitors?
- NanoViricides's key competitors include Gilead Sciences, Pfizer, Merck & Co., and others. These companies compete in similar markets and product categories.
- Where is NanoViricides headquartered?
- NanoViricides is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2005.